Jiangxi Shimei Pharmaceutical Co., Ltd.

Main study objectives Healthy subjects were given a single oral dose of the test preparation Sitagliptin Metformin Tablets (II) (specification: 50mg/850mg) produced by Jiangxi Shimei Pharmaceutical Co., Ltd. or the reference preparation Sitagliptin Metformin Tablets (II) (trade name: JENODA; specification: 50mg/850mg) produced by Patheon Puerto Rico, Inc. (Manati)(United States) in the fasting or postprandial state to investigate the pharmacokinetic parameters of the test preparation and the reference preparation in healthy subjects, respectively, and to evaluate the bioequivalence of the two preparations. Secondary study objectives Investigate the safety of the test preparation and the reference preparation in healthy subjects.

To verify the superiority of the combination preparation over the single preparation: To evaluate the efficacy and safety of bisoprolol levamlodipine tablets (5mg/2.5mg) in patients with primary mild to moderate hypertension whose blood pressure cannot be effectively controlled by monotherapy with bisoprolol fumarate tablets (5mg) or amlodipine besylate tablets (5mg) for 4 weeks.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation fluvastatin sodium sustained-release tablets (specification: 80 mg, produced by Jiangxi Shimei Pharmaceutical Co., Ltd.) and the reference preparation fluvastatin sodium sustained-release tablets (trade name: Lescol; specification: 80 mg, produced by Beijing Novartis Pharmaceutical Co., Ltd.) in healthy Chinese adult subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study: to evaluate the safety of the test preparation fluvastatin sodium sustained-release tablets and the reference preparation Lescol in healthy Chinese adult subjects.